Skip to content

LB制药

US · LBRX #3180 按市值排名 上市于 2025
36.74 +0.05 +0.14%
实时 - 追踪5344个代码 - 心跳于28秒前 · 2026-10-16 19:30

最新新闻

  • 评级变动
    Craig-Hallum Keeps Their Buy Rating on LB Pharmaceuticals, Inc. (LBRX)
    TipRanks · 2026/5/13
  • 评级变动
    Piper Sandler Maintains LB Pharmaceuticals(LBRX.US) With Buy Rating, Maintains Target Price $78
    \u5e02\u573a\u8d44\u8baf · 2026/8/3
  • 评级变动
    Wolfe Research Initiates LB Pharmaceuticals(LBRX.US) With Buy Rating, Announces Target Price $45
    \u5e02\u573a\u8d44\u8baf · 2026/7/7
  • Needham Initiates LB Pharmaceuticals(LBRX.US) With Buy Rating, Announces Target Price $68
    \u5e02\u573a\u8d44\u8baf · 2026/10/2
  • Clear Street Maintains LB Pharmaceuticals(LBRX.US) With Buy Rating, Maintains Target Price $69
    \u5e02\u573a\u8d44\u8baf · 2026/8/21
  • 评级变动
    Stifel Maintains LB Pharmaceuticals(LBRX.US) With Buy Rating, Raises Target Price to $53
    \u5e02\u573a\u8d44\u8baf · 2026/8/13
  • 评级变动
    Roth MKM Maintains LB Pharmaceuticals(LBRX.US) With Buy Rating, Raises Target Price to $37
    \u5e02\u573a\u8d44\u8baf · 2026/5/18
  • 评级变动
    Analysts Offer Insights on NA Companies: Exodus Movement, Inc. Class A (EXOD) and LB Pharmaceuticals, Inc. (LBRX)
    TipRanks · 2026/7/22
  • 评级变动
    Clear Street Initiates LB Pharmaceuticals(LBRX.US) With Buy Rating, Announces Target Price $45
    \u5e02\u573a\u8d44\u8baf · 2026/5/27
  • 评级变动
    LB Pharmaceuticals, Inc. (LBRX) Gets a Buy From H.C. Wainwright
    TipRanks · 2026/6/25
  • 评级变动
    Analysts Offer Insights on NA Companies: Evommune, Inc. (EVMN), LB Pharmaceuticals, Inc. (LBRX) and SpaceX (SPCX)
    TipRanks · 2026/8/3
  • Earnings Flash (LBRX) LB Pharmaceuticals Posts Q2 Loss $1.71 a Share, Vs. FactSet Est of $0.81 Loss
    MT Newswires · 2026/8/11
  • 评级变动
    Craig-Hallum Remains a Buy on LB Pharmaceuticals, Inc. (LBRX)
    TipRanks · 2026/8/12
  • H.C. Wainwright Maintains LB Pharmaceuticals(LBRX.US) With Buy Rating, Raises Target Price to $60
    \u5e02\u573a\u8d44\u8baf · 2026/8/24
  • 评级变动
    Roth MKM Maintains LB Pharmaceuticals(LBRX.US) With Buy Rating, Maintains Target Price $37
    \u5e02\u573a\u8d44\u8baf · 2026/5/18
  • 评级变动
    H.C. Wainwright Maintains LB Pharmaceuticals(LBRX.US) With Buy Rating, Maintains Target Price $45
    \u5e02\u573a\u8d44\u8baf · 2026/8/3
  • 评级变动
    Craig-Hallum Maintains LB Pharmaceuticals(LBRX.US) With Buy Rating, Announces Target Price $36
    \u5e02\u573a\u8d44\u8baf · 2026/5/13
  • Clear Street Maintains LB Pharmaceuticals(LBRX.US) With Buy Rating, Raises Target Price to $69
    \u5e02\u573a\u8d44\u8baf · 2026/8/21
  • 评级变动
    Craig-Hallum Maintains LB Pharmaceuticals(LBRX.US) With Buy Rating, Maintains Target Price $36
    \u5e02\u573a\u8d44\u8baf · 2026/6/11
  • 评级变动
    Analysts Offer Insights on NA Companies: AEVEX Corp. Class A (AVEX), LB Pharmaceuticals, Inc. (LBRX) and BETA Technologies, Inc. Class A (BETA)
    TipRanks · 2026/8/13

新闻标题为自动聚合内容,未经我们团队独立核实或编辑。

报价时间 2026-10-16 19:30:04 · 仅供参考,不构成投资建议,也未考虑您的具体情况。

LB制药 讨论区 0 条评论

发表评论